Unbiased Analysis of Today's Healthcare Issues
That is the title of an article in AJMC co-authored with Meena Venkatachalam. An excerpt is below: While decision-makers traditionally have ignored the issue of inequality, academic researchers have already developed tools to quantify a treatment’s value from reductions in inequality. Two common methods for doing so are distributional cost effectiveness analysis (DCEA) and multiple-criteria…
I’m very excited to announce that the study: “Alternative payment models and innovation: A case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure” has been published in the Journal of Medical Economics last week. Co-authors on the paper are Elmar R. Aliyev, Michelle Brauer, Siyeon Park and Xian…
“Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis” is the title of a paper recently published in BMJ Open with co-authors Howard Thom, Jeroen Jansen, Lauren Zhao, George Joseph, Hung-Yuan Cheng, Subhajit Gupta, and Nirmish Shah. The abstract is below. Objectives Treatment options for preventing vaso-occlusive crises (VOC) among…
This is the title of a paper published in Letters in Biomathematics with colleagues Anuj Mubayi, Jeff Sullivan, Oliver Diaz, Aditi Ghosh, Anamika Mubayi, Olcay Akman, and Phani Veeranki. The subtitle is: “The Coupled Dynamics of the COVID-19 Pandemic with Social Epidemics“. The abstract is below. Policymakers are under intense pressure to respond effectively to…
That is the title of my recent blog post in Health Affairs with my co-author Meena Venkatachalam. The subtitle is “Expanding Value Assessment To Incorporate Health Inequality“. An excerpt is below: The brutal murder of George Floyd has brought renewed attention to systemic inequality that African Americans and other minorities face in the United States…
That is the title of my commentary with co-authors Kathy Lang and Ross Maclean in the Journal of Clinical Pathways. The abstract is below. What is the right price for a new treatment for COVID-19? One common approach—which is frequently used worldwide and in the United States by the Institute of Clinical and Economic Review—measures…
Tomorrow, Monday, May 18, I will be moderating a panel with Dr. Bapu Jena of Harvard University, Elizabeth Oyekan of PRECISIONvalue and Michael Barr of National Committee for Quality Assurance (NCQA). The topic is: WILL ALTERNATIVE PAYMENT MODELS INCENTIVIZE HEALTH SYSTEMS TO PRESCRIBE HIGH VALUE MEDICATIONS AND SUPPORT BETTER CLINICAL OUTCOMES? ISSUE:Recent decades have seen…
This is the title of my article at pharmaphorum. The precis of the article is below. The Institute for Clinical and Economic Review (ICER) measures the value of new drugs and health technologies, but faces a number of key challenges such as keeping their assessments up to date with new evidence, allowing for different perspectives…
Who knows best, patients or physicians? Clearly, physicians have medical knowledge that patients do not. On the other hand, patients have their own preferences balancing treatment safety, efficacy, convenience and other factors. Further, physicians may be more familiar with older less effective treatments compared to newer more effective treatments. One interesting question is how health…
This is the title of my recent commentary in the Journal of Clinical Pathways. The article discusses a number of challenges of measuring quality of care in oncology: The challenges mentioned included: the long time-lag to develop new guidelines and then incorporate these into validated quality measures, the potential narrow populations to which guidelines would…